What factors drive inclusion of genes in a hereditary cancer multi-gene panel?

• A. Clinical guidelines, cancer risk associations, and penetrance determine inclusion
• B. Random selection
• C. Test budget only
• D. Patient preference only

Answer: (A)

Inclusion of genes on a hereditary cancer panel is guided by how strongly a gene is linked to cancer and how useful testing that gene would be for patient care. Professional guidelines synthesize the best available evidence to specify which genes have established cancer risk associations and when testing them changes management. Penetrance matters because it represents how likely a pathogenic variant in a gene is to result in cancer; genes with high penetrance provide clearer, more actionable information for surveillance, risk-reducing measures, or treatment decisions. When a gene has solid evidence of cancer risk and meaningful penetrance, and testing for it improves clinical care, it belongs on the panel.

Relying on random selection, budget alone, or patient preference alone does not ensure that the panel provides clinically useful information. Random or budget-driven choices can include genes with uncertain significance or unclear impact on management, while patient preference without evidence-based guidance may not align with what actually improves outcomes.